Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Gastrointestinal Cancers | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition (Companion Faculty Lecture)

32:57
 
Share
 

Manage episode 412890709 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics:

  • Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00)
  • Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56)
  • Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52)
  • Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11)
  • Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56)
  • Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39)

CME information and select publications

  continue reading

1363 episodes

Artwork
iconShare
 
Manage episode 412890709 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics:

  • Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00)
  • Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56)
  • Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52)
  • Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11)
  • Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56)
  • Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39)

CME information and select publications

  continue reading

1363 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide